Skip to content

EFFECT OF ERAND TAIL IN TREATMENT OF LOWER BACK PAIN

A COMPARATIVE CLINICAL STUDY TO EVALUATE THE ROLE OF ERAND TAIL IN MANAGEMENT OF GRIDHRASI (~PROLAPSED INTERVERTEBRAL DISC)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017244
Enrollment
50
Registered
2019-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G55- Nerve root and plexus compressionsin diseases classified elsewhere

Interventions

Intervention1: Erand Tail: 50 patients will be randomly selected for this group and they will be treated for 14 days as under. 1. Sarvang Abhyanga with Laghu Vishgarbh Tail. 2. Sarvang vashp Swedan wi

Sponsors

Chaudhary Brahm Prakash Ayurved Charak Sansthan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases will be selected randomly regardless of sex, occupation, and socioeconomic status. 2. Patients between the age group of 20-60 years. 3. Patients having clinical features of Gridhrasi as described in Carak Samhita.(pain and stiffness in lower back radiating to lower limb). 4. The patients should full fill SLR positive at 40 degree or less and positive Lasegue test for Prolapsed inter vertebral disc. 5. Patients having VAS score 3-8. 6. Patients having Oswestry disability index 21-80%.

Exclusion criteria

Exclusion criteria: 1. Patients with back pain associated with traumatic injury to spine, inflammatory arthritis, infective arthritis, Monoplegia, Paraplegia. 2. Patients Suffering with Cauda equina syndrome. 3. Patients having associated Cardiac disease, Tuberculosis, Malignant Hypertension, impairment of Liver functions, Malignancy, HIV-AIDS, G.I. disorders etc. 4. Pregnant and lactating women. 5. Patients having other complications.

Design outcomes

Primary

MeasureTime frame
Reduction of Stambh (Stiffness) Reduction of Ruk (Pain) Reduction of Spandate muhu (Pulsatile pain) Reduction of Tandra (Drowsiness) Reduction of Gaurav (Heaviness) Reduction of Arochaka (Loss of appetite) Timepoint: 21 days

Secondary

MeasureTime frame
Assessment of reduction in the level of abdominal discomfort pain and Frequency of defecation during use of trial medicinesTimepoint: level of abdominal discomfort pain and Frequency of defecation on 0 day 7th day 14th day and 21st day

Countries

India

Contacts

Public ContactDr Ritu Kumari

Ch. Brahm Prakash Ayurved Charak Sansthan

naimishraj@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026